Get in touch with BioViros
+64 21 402 487


Fast-Track Your Due Diligence

Fast Delivery of Investor

Updates and Support



We are continuously updating our investor information. Visitors signed up to our Investor Pack will receive notes when documents are updated or new numbers released. 


NZ$2.5M Bridge Round

NZ$0.5M Committed Funding

August 2023

Investor Summary as .pdf

Get Instant Access to

1. The wholesale investor pack from founder - Dr. Marina Rajič

2. Notifications for real time updates and monthly reports to our investors.

Get | Wholesale Investor Pack

Marina Rajic


Raising Strategy

Raising our bridge round by Q4/23

  • Commitment to GMP facility in New Zealand
  • Development milestone: increase production yield
  • Scale marketing and sales: Sign customers for clinical grade manufacture
  • Next inflection point in 2025 Growth equity.

Back To Top -->|

Market Size

  • Oncology counts for over 60% of total market.
  • CAR-T therapies in the global cell and gene therapy market is expected to grow from 82.73% in 2022 to 90.32% by 2030.
  • Eight out of 15 FDA approved cell and gene therapies use lentiviral vectors.

Back To Top -->|

Global Cell and Gene Therapy TAM

NZ$ 30.8B  in 2022

NZ$ 155.1B by 2030

%22.4  CAGR

Updated June 2023


Global LVV Manufacture Market 

NZ$ 2.4B TAM

NZ$ 1.3B SAM

%11.9 CAGR

Updated June 2023


Bridge Round

Raising NZ$ 2.5M by Q4/23

Our bridge round is an important stepping stone to scale operations crucial for meeting the growing demand in the cell and gene therapy sector.
This round enables us to reach key milestones that can significantly increase our companies value & setting the stage for a successful Growth Capital in 2025. 

August 2023

How To Invest

  1. Register for the wholesale investor pack
  2. Meet the founder
  3. Sign CDA, and receive access to Data Room
  4. Complete due diligence 
  5. Close the deal
Estimated time from first registration to closed deal:
3 months

Back To Top -->|

Investing in New Zealand

There are many benefits for choosing New Zealand.

  • Highly skilled workforce
  • Supportive government
  • Favorable regulatory environment
  • A strong economy
  • An attractive place to work

Overall, New Zealand is an excellent location for biotech CDMOs. The country has a number of advantages that make it an attractive option for companies to develop and manufacture high value biological products.

Trans-Pacific Partnership

New Zealand is a member of the Trans-Pacific Partnership (TPP). Some of our benefits are.

  • Reduced tariffs among member countries
  • Enhanced intellectual property rights
  • Regulatory coherence streamline regulations among member countries
  • Easier access to markets of all member countries
  • Supply chain efficiency
  • The TPP includes provisions that protect foreign investments
  • High labor and environmental standards

Experienced Leadership
Benefit from the expertise of an experienced leadership team. BioViros is backed by Bridgewest Group.

Lab Team
Hannah Pearce
Hannah Pearce, Ph.D.

Biotech Development Scientist

Ellie Torbati, Ph.D.

Biotech Research Scientist

Sofia Grey
Sofia Gray

Intern - Process Development Assistant

Isabella Lovalvo
Isabella Lovalvo

Student Intern - University of California, Berkeley

Marina Rajič, Ph.D.
Marina Rajic, Ph.D.

Founder & CEO

Tom VanCott
Tom VanCott, Ph.D.

Director, Chairman

Saum Vahdat
Saum Vahdat


John Robson
John Robson


Farzad Haerizadeh, Ph.D.
Farzad Haerizadeh, Ph.D.

Scientific Advisor

Stephen Chang, Ph.D.
Stephen Chang, Ph.D.

Scientific Advisor

Rick Hancock
Rick Hancock

Strategic Advisor

BioViros-Brand_IconOnly-Red Consider BioViros as an Investment

Action Required

Bridge fundraising will end in Q4/2023. Get the info.

Get | Wholesale Investor Pack


Explore our Mission --->|